Product Description: Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase[1][2].
Applications: COVID-19-immunoregulation
Formula: C5H3N5O2S3
References: [1]De SK, et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2009 Apr 9;52(7):1943-52./[2]Augustine C, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro. Neuroscience. 2014 Aug 22;274:1-10./[3]Serizawa F, et al. Pretreatment of human cerebrovascular endothelial cells with CO-releasing molecule-3 interferes with JNK/AP-1 signaling and suppresses LPS-induced proadhesive phenotype. Microcirculation. 2015 Jan;22(1):28-36.
CAS Number: 40045-50-9
Molecular Weight: 261.30
Compound Purity: 98.03
Research Area: Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 62.5 mg/mL (ultrasonic)
Target: JNK
Deutsch
English
